Last update:

Clinical pharmacology news

GLP-1 agonist drugs show digestive side effects but may help fight infections

Originally developed to treat diabetes, a class of drugs known as glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are now stepping into the spotlight as weight loss drugs. A recent umbrella review draws attention to ...

First-in-class molecules dial down inflammation without compromising immunity

Scripps Research scientists have developed a new class of drug compounds that reduce harmful inflammation while leaving the body's ability to fight infections intact—a long-sought goal in treating autoimmune diseases. The ...

Zebrafish reveal new insights into the biology of autism

In recent decades, the zebrafish has become one of the most valuable model organisms in scientific research. For a variety of reasons, including their genetic similarities to humans, these tiny tropical fish have helped researchers ...

New pill could change plaque psoriasis treatment

Folks with severe plaque psoriasis often have to choose between convenient pills that don't work very well or highly effective injections that come with the hassle of needles. That trade-off may soon change. New clinical ...

FDA approves new weight loss pill in record time

A new daily pill to help with weight loss has been approved by the U.S. Food and Drug Administration (FDA), and it moved through review faster than most drugs in recent years.

Poison centers see jump in kava calls

Calls to poison centers about kava—a drug found in drinks marketed as a healthy alternative to alcoholic beverages—rose 383% between 2011 and 2025, according to a new UVA Health study. The findings have been published in ...

Probing a paradoxical drug response for irregular heartbeat

Irregular heartbeat, or arrhythmia, can be treated with various procedures or medication, but not all medications work for all patients. In fact, one arrhythmia medication can actually cause arrhythmia in people with a common ...

Understanding GLP-1 signaling: A path to better therapies

About one in eight U.S. adults are currently taking a GLP-1 drug such as Ozempic, Wegovy, or Zepbound to treat diabetes, obesity, or other conditions, according to a KFF Health Tracking poll. But many suffer from significant ...

FDA approves Dupixent for allergic fungal rhinosinusitis

The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult and pediatric patients aged 6 years and older with allergic fungal rhinosinusitis (AFRS) and a history of sino-nasal surgery.